Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director · PRESIDENT AND CEO | February 28, 2025 | March 04, 2025 |
| ZEVRA THERAPEUTICS, INC.KMPH · Entity 5212 | Director | November 28, 2022 | November 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date February 28, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,109 |
Reported balance
After 2025-02-28 transaction · row 1
1 source rowRow 1 · 2025-02-28 · Sale · Disposed 583 · Balance 13,109 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
ZEVRA THERAPEUTICS, INC.
Report date November 28, 2022 · Filed November 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2032-11-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-11-28 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 4, 2025 21:59 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 583 | $4.75 | $2,769.25 |
DisclosureSEC source: 0001415889-25-006576 · form4-03042025_090317.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,109 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 00:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 372 | $4.72 | $1,755.84 |
DisclosureSEC source: 0001415889-25-003295 · form4-02072025_120231.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,692 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 21:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,668 | $0.29 | $1,063.72 |
DisclosureSEC source: 0001415889-24-026248 · form4-11062024_091118.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,768 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 20:05 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,149 | $0.35 | $1,452.15 |
DisclosureSEC source: 0001415889-24-020605 · form4-08022024_040806.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,436 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 02, 2024 Filed May 6, 2024 20:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,936 | $0.75 | $2,952.00 |
DisclosureSEC source: 0001415889-24-012322 · form4-05062024_040544.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,585 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,834 | $0.89 | $5,192.26 |
DisclosureSEC source: 0001415889-24-006273 · form4-03042024_090323.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,521 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 35,575 | $0.53 | $18,854.75 |
DisclosureSEC source: 0001415889-24-003395 · form4-02122024_100215.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,355 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,981 | $0.55 | $2,739.55 |
DisclosureSEC source: 0001415889-24-002513 · form4-02052024_090257.xml · nonDerivative · entry 2 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,930 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002513 · form4-02052024_090257.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,911 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 20:37 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,796 | $1.22 | $4,631.12 |
DisclosureSEC source: 0001209191-23-054332 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,411 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:21 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,307 | $3.07 | $13,222.49 |
DisclosureSEC source: 0001209191-23-044636 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,207 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,869 | $4.40 | $17,023.60 |
DisclosureSEC source: 0001209191-23-028247 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,514 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,987 | $9.71 | $58,133.77 |
DisclosureSEC source: 0001209191-23-016796 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,383 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001209191-23-015553 · doc4.xml · derivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 23:38 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,191 | $11.80 | $49,453.80 |
DisclosureSEC source: 0001209191-23-007170 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,370 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021 and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:23 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 14,470 | $11.13 | $161,051.10 |
DisclosureSEC source: 0001209191-22-057948 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,561 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.13 to $11.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 21:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,006 | $12.67 | $25,416.02 |
DisclosureSEC source: 0001209191-22-023237 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,031 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on May 28, 2021 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 121,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-22-013988 · doc4.xml · derivative · entry 2 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,000 Underlying: Common Stock · 121,000 shares Expires 2032-02-25 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013988 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,037 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 12:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 566,000 | $0.00 Strike: $16.83 | $0.00 |
DisclosureSEC source: 0001209191-21-062593 · doc4.xml · derivative · entry 3 Posner Christopher · CIK 0001748265 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,000 Underlying: Common Stock · 566,000 shares Expires 2031-10-29 F3 · derivative.exercise_date: 25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 12:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 142,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 2 Posner Christopher · CIK 0001748265 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,037 F2 · shares: Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 12:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 5,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,037 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 23:33 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,304 | $13.04 | $30,044.16 |
DisclosureSEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 2 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,096 F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:33 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-21-038764 · doc4.xml · derivative · entry 3 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2031-06-03 F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:33 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 01:28 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $15.82 | $31,638.00 |
DisclosureSEC source: 0001209191-20-060097 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $15.62 | $0.00 |
DisclosureSEC source: 0001209191-20-035060 · doc4.xml · derivative · entry 2 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2030-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035060 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:03 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $20.44 | $0.00 |
DisclosureSEC source: 0001209191-19-035225 · doc4.xml · derivative · entry 2 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:03 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035225 · doc4.xml · nonDerivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:54 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-18-045588 · doc4.xml · derivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-08-02 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable in three equal annual installments beginning on August 2, 2019, subject to the reporting person's continued service as a director through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.